Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01464320 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.
A Phase 1 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01464320 is a Phase 1 study that has completed, run by Abbott. The registered enrollment target is 16 participants.
The verdict
NCT01464320, a Phase 1 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
To assess the safety, tolerability and pharmacokinetics of ABT-614 in subjects with type 2 diabetes and chronic kidney disease with albuminuria and to determine whether ABT-614 reduces glomerular filtration rate.
Interventions
- DRUG Placebo Comparator
- DRUG ABT-614
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01464320
The ClinicalTrials.gov registry entry for NCT01464320 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT01464320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01464320 about?
NCT01464320 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.". To assess the safety, tolerability and pharmacokinetics of ABT-614 in subjects with type 2 diabetes and chronic kidney disease with albuminuria and to determine whether ABT-614 reduces glomerular filtration rate.
What is the current status of trial NCT01464320?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2011-11. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01464320?
The interventions under investigation include: Placebo Comparator (DRUG), ABT-614 (DRUG).
Who is sponsoring clinical trial NCT01464320?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.